Université Grenoble Alpes, Inserm U1055, Laboratoire de Bioénergétique Fondamentale et Appliquée (LBFA), Grenoble, France.
Cell death and Childhood Cancers Laboratory, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon1, Centre Léon Bérard, LabEx DEVweCAN, Institut Convergence Plascan, Lyon, France.
Cell Death Dis. 2024 May 2;15(5):311. doi: 10.1038/s41419-024-06668-9.
Cancer cells are highly dependent on bioenergetic processes to support their growth and survival. Disruption of metabolic pathways, particularly by targeting the mitochondrial electron transport chain complexes (ETC-I to V) has become an attractive therapeutic strategy. As a result, the search for clinically effective new respiratory chain inhibitors with minimized adverse effects is a major goal. Here, we characterize a new OXPHOS inhibitor compound called MS-L6, which behaves as an inhibitor of ETC-I, combining inhibition of NADH oxidation and uncoupling effect. MS-L6 is effective on both intact and sub-mitochondrial particles, indicating that its efficacy does not depend on its accumulation within the mitochondria. MS-L6 reduces ATP synthesis and induces a metabolic shift with increased glucose consumption and lactate production in cancer cell lines. MS-L6 either dose-dependently inhibits cell proliferation or induces cell death in a variety of cancer cell lines, including B-cell and T-cell lymphomas as well as pediatric sarcoma. Ectopic expression of Saccharomyces cerevisiae NADH dehydrogenase (NDI-1) partially restores the viability of B-lymphoma cells treated with MS-L6, demonstrating that the inhibition of NADH oxidation is functionally linked to its cytotoxic effect. Furthermore, MS-L6 administration induces robust inhibition of lymphoma tumor growth in two murine xenograft models without toxicity. Thus, our data present MS-L6 as an inhibitor of OXPHOS, with a dual mechanism of action on the respiratory chain and with potent antitumor properties in preclinical models, positioning it as the pioneering member of a promising drug class to be evaluated for cancer therapy. MS-L6 exerts dual mitochondrial effects: ETC-I inhibition and uncoupling of OXPHOS. In cancer cells, MS-L6 inhibited ETC-I at least 5 times more than in isolated rat hepatocytes. These mitochondrial effects lead to energy collapse in cancer cells, resulting in proliferation arrest and cell death. In contrast, hepatocytes which completely and rapidly inactivated this molecule, restored their energy status and survived exposure to MS-L6 without apparent toxicity.
癌细胞高度依赖生物能量过程来支持其生长和存活。代谢途径的破坏,特别是通过靶向线粒体电子传递链复合物(ETC-I 到 V),已成为一种有吸引力的治疗策略。因此,寻找具有最小不良反应的临床有效新型呼吸链抑制剂是主要目标。在这里,我们描述了一种称为 MS-L6 的新型 OXPHOS 抑制剂化合物,它作为 ETC-I 的抑制剂,结合了 NADH 氧化抑制和解偶联作用。MS-L6 对完整和亚线粒体颗粒都有效,表明其功效不依赖于其在线粒体中的积累。MS-L6 降低了 ATP 的合成,并在癌细胞系中诱导代谢转变,增加葡萄糖消耗和乳酸生成。MS-L6 以剂量依赖性方式抑制多种癌细胞系的细胞增殖或诱导细胞死亡,包括 B 细胞和 T 细胞淋巴瘤以及儿科肉瘤。酿酒酵母 NADH 脱氢酶(NDI-1)的异位表达部分恢复了 MS-L6 处理的 B 淋巴细胞瘤细胞的活力,表明 NADH 氧化的抑制与其细胞毒性作用在功能上相关。此外,MS-L6 给药在两种小鼠异种移植模型中诱导强烈抑制淋巴瘤肿瘤生长,而无毒性。因此,我们的数据表明 MS-L6 是一种 OXPHOS 抑制剂,其对呼吸链有双重作用机制,并在临床前模型中具有强大的抗肿瘤特性,将其定位为一类有前途的药物的先驱成员,有待评估用于癌症治疗。MS-L6 对线粒体具有双重作用:ETC-I 抑制和 OXPHOS 解偶联。在癌细胞中,MS-L6 对 ETC-I 的抑制作用至少比在分离的大鼠肝细胞中高 5 倍。这些线粒体作用导致癌细胞能量崩溃,导致增殖停滞和细胞死亡。相比之下,完全和快速失活这种分子的肝细胞恢复了它们的能量状态,并在没有明显毒性的情况下存活下来,而不受 MS-L6 的影响。
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2022-9-26
Signal Transduct Target Ther. 2025-8-4
Cell Rep. 2025-4-22
Cancers (Basel). 2022-12-22
Int J Mol Sci. 2022-11-10
Cancers (Basel). 2022-11-11
Antioxidants (Basel). 2022-11-7